中國醫藥(600056.SH):通用三洋獲三份注射用鹽酸頭孢替安《藥品註冊批件》
格隆匯12月30日丨中國醫藥(600056.SH)公佈,公司於2019年12月21日發佈《關於子公司藥物註冊的提示性公告》,披露了公司下屬全資子公司海南通用三洋藥業有限公司(以下簡稱“通用三洋”)關於注射用鹽酸頭孢替安藥品註冊申請的進展情況。
近日,通用三洋收到國家藥品監督管理局核准簽發的三份注射用鹽酸頭孢替安《藥品註冊批件》。
鹽酸頭孢替安是由日本武田藥品工業株式會社研製開發的第二代頭孢菌素類抗生素,1981年首次在日本上市,原研產品的規格有0.25g、0.5g和1.0g三種。該藥品主要適用於對本品敏感的葡萄球菌屬、鏈球菌屬(腸球菌除外)、肺炎球菌、流感桿菌、大腸桿菌、克雷伯桿菌屬、腸道菌屬、枸櫞酸桿菌屬、奇異變形桿菌,普通變形桿菌,雷特格氏變形桿菌,摩根氏變形桿菌等所致的感染。
作為第二代頭孢菌素類抗生素,鹽酸頭孢替安抗菌譜廣泛而均衡,對革蘭氏陰性菌及陽性菌都顯示了廣泛的抗菌作用,克服了第一代頭孢菌素對革蘭氏陰性菌無抗菌作用和第三代頭孢菌素對革蘭氏陽性菌抗菌作用弱的特點,其對革蘭陰性菌和陽性菌都有廣泛的抗菌作用,尤其對大腸桿菌、克雷白桿菌屬、奇異變形桿菌,流感桿菌等,顯示了更強的抗菌活性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.